Addiction risks from opioid drugs stem from their targeting of receptors in the central nervous system. SiteOne Therapeutics is developing non-opioid approaches to treating pain by focusing on sodium channels in the peripheral nervous system. NaV1.7 and NaV1.8 are key channels that transmit pain signals, with SiteOne’s lead program targeting NaV1.7. The company’s technology enables the identification of selective molecules for these channels. SiteOne has secured $100 million in financing and is advancing towards Phase 2 testing. The potential applications of sodium channel targeting extend beyond pain, including the treatment of cough. Vertex Pharmaceuticals and Amgen have collaborated with SiteOne on sodium channel research.
Source link
Startup SiteOne Secures $100M to Forge Ahead With Novel Non-Opioid Pain Meds
